Serum miR-373 was significantly upregulated in HER2-negative (p < 0.001), ER-positive (p < 0.005), and PR-positive (p < 0.024) BC patients, while serum miR-155 was significantly upregulated in PR-negative (p < 0.001) BC patients. The gene discussed is ERBB2; the disease is breast cancer.